Clinical trials: Coronary Stent Occlusion
Coronary Artery Disease
Prevention of Restenosis After Genous Stent Implantation Using a Paclitaxel Eluting Balloon in Coronary Arteries
Percutaneous coronary intervention with stent implantation is limited on the one hand by restenosis due to smooth muscle cell proliferation and on the other hand by stent thrombosis due to incomplete or not sufficient enough…
- Trial name
- NCT00732953
- Testing
- Genous stent implantation with paclitaxel-eluting balloon dilation, Genous stent implantation
- Where
- 3 sites in Germany
- Volunteers
- 120 people
- Sponsor
- University of Ulm
Left Main Coronary Artery Stenosis
Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)
The management of patients with unprotected left main coronary artery (LMCA) disease undergoing percutaneous coronary intervention (PCI) in contemporary interventional cardiology practice remains matter of intense debate.
- Trial name
- ULTIMATE-LM (NCT05650411)
- Testing
- LMCA PCI with Supraflex Cruz ultrathin-strut biodegradable polymer sirolimus-eluting stent (Sahajanand Medical Technologies Ltd., Surat, India)., P2Y12 inhibitor-based SAPT after short DAPT, Conventional DAPT
- Where
- Switzerland
- Volunteers
- 828 people
- Sponsor
- IGLESIAS Juan Fernando
Coronary Artery Disease
Drug-Coated Balloon in Anticoagulated and Bleeding Risk Patients Undergoing PCI
The purpose of this study is to compare DCB with DES in stable CAD or ACS patients who are at high risk of bleeding. The hypothesis of the DEBATE trial is that the strategy using DCB and a shorter DAPT regimen is non-inferior to…
- Trial name
- DEBATE (NCT04814212)
- Testing
- Percutaneous coronary intervention using drug-coated balloon, Percutaneous coronary intervention using drug-eluting stent
- Where
- 14 sites in Finland, France and 2 more
- Volunteers
- 546 people
- Sponsor
- North Karelia Central Hospital
Coronary Artery Disease
The Efficacy of CILostazol ON Ischemic Complications After DES Implantation
Objectives : To evaluate the influence of concomitant use of cilostazol with aspirin and clopidogrel on the composite cardiovascular adverse outcomes (cardiac death, myocardial infarction, nonhemorrhagic stroke, target lesion…
- Trial name
- CILON-T (NCT00776828)
- Testing
- cilostazol
- Where
- South Korea
- Volunteers
- 960 people
- Sponsor
- Seoul National University Hospital
Coronary Artery Diseases
BIOFLOW III Satellite-Italy Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). 500 subjects will be enrolled in this registry.
- Trial name
- NCT02028728
- Where
- 18 sites in Italy
- Volunteers
- 609 people
- Sponsor
- Biotronik Italia S.p.A.
Coronary Artery Disease
Evaluation of Effectiveness and Safety of Ultimaster™ Tansei™ Stent and/or Ultimaster Nagomi™ Stent in Routine Clinical Practice
This study is to evaluate the effectiveness and safety of Ultimaster Tansei stent and/or Ultimaster Nagomi stent in the "real-world" daily practice.
- Trial name
- IRIS Tansei (NCT04443530)
- Testing
- Ultimaster™ Tansei™ stent and/or Ultimaster Nagomi™ stent
- Where
- 11 sites in South Korea
- Volunteers
- 2,000 people
- Sponsor
- Duk-Woo Park, MD
Coronary Disease, Coronary Artery Disease
XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study
XIENCE V® India is a prospective, open-label, multi-center, observational, single-arm study to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- XIENCE V India (NCT00631228)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent
- Where
- 18 sites in India
- Volunteers
- 1,000 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Effectiveness of Clopidogrel Resinate in PCI(PRIDE)
This study is an open label, multi-center, randomized trial, which is designed to evaluate the efficacy and safety of clopidogrel derivative (Pregrel®) therapy for 12 months in patients undergoing PCI compared to conventional…
- Trial name
- NCT01349777
- Testing
- Pregrel®, Plavix®
- Where
- 3 sites in South Korea
- Volunteers
- 1,056 people
- Sponsor
- Seung-Jung Park
Atherosclerosis
PE PREMIER CHINA CLINICAL TRIAL
PE PREMIER China: A Prospective, Multicenter Trial to Assess the Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)
- Trial name
- NCT02230254
- Testing
- Percutaneous coronary intervention PROMUS PREMIER
- Volunteers
- 101 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease, Diabetes Mellitus
EverolimuS-ElUtinG BioresorbAble VasculaR Scaffolds vErsus EVerolimus-Eluting Stents in Patients With Diabetes Mellitus
Prospective, randomized, controlled, multicenter, open-label study to compare everolimus-eluting bioresorbable vascular scaffolds to everolimus-eluting stents in patients with diabetes mellitus.
- Trial name
- SUGAR-EVE (NCT02632292)
- Testing
- Absorb GT1, Promus
- Where
- Germany
- Volunteers
- 33 people
- Sponsor
- University of Luebeck
Acute Coronary Syndrome, Lipid Disorder
Polypill in Acute Coronary Syndrome
Acute coronary syndromes (ACS) represent a major contributor to mortality, morbidity, and healthcare costs. Effective therapies are widely available; however, adherence is low.
- Conditions
- Acute Coronary Syndrome, Lipid Disorder, Coronary Artery Disease
- Trial name
- POLY-ACS (NCT05514938)
- Testing
- Polypill, Usual Care (individual medications prescribed by primary cardiologist)
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- University of Texas Southwestern Medical Center
Stent Restenosis, Coronary Artery Disease
Effect of Exercise Training in Coronary Artery Disease Patients After Stenting
To determine the effects of exercise training on ankle-brachial index and Quality of Life in coronary artery disease patients after stenting.
- Trial name
- NCT05315193
- Testing
- Structured In-patient and Home plan, Conventional Therapy
- Where
- Pakistan
- Volunteers
- 73 people
- Sponsor
- Riphah International University
Coronary Artery Disease
Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing
Objectives 1. To evaluate the safety and long-term effectiveness of coronary stenting with the Everolimus-eluting coronary stent system(EECSS) (XIENCETM V, Abbott Vascular, Santa Clara, CA, PromusTM, Boston Scientific, Natick…
- Trial name
- EXCELLENT (NCT00698607)
- Testing
- Everolimus-eluting stent (Xience or Promus), Sirolimus-eluting stent (Cypher), 6-month clopidogrel therapy
- Where
- South Korea
- Volunteers
- 1,466 people
- Sponsor
- Seoul National University Hospital
Coronary Artery Disease
A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES)
PIONEER-II OPC trial is a prospective, multicenter, single-arm registry trial. 1000 subjects from approximately 40 interventional cardiology centers will be enrolled to evaluate the target lesion failure(TLF) as the primary…
- Trial name
- OPC (NCT02698852)
- Testing
- BuMA Supreme
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Sino Medical Sciences Technology Inc.
Coronary Artery Disease
SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System
The purpose of the SPIRIT IV Clinical Trial is to continue to evaluate the safety and efficacy of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V®).
- Trial name
- NCT00307047
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent, TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
- Where
- 65 sites in United States
- Volunteers
- 3,687 people
- Sponsor
- Abbott Medical Devices
Atrial Fibrillation, Coronary Artery Disease
The Greek AntiPlatElet Atrial Fibrillation Registry.
Approximately 5% to 7% of patients undergoing percutaneous coronary intervention for the treatment of coronary artery disease, require chronic oral anticoagulation on top of aspirin and a P2Y12 receptor antagonist, mainly due to…
- Trial name
- GRAPE-AF (NCT03362788)
- Testing
- VKA, NOAC
- Where
- Greece
- Volunteers
- 654 people
- Sponsor
- Attikon Hospital
Coronary Artery Disease
Clinical Management of Antiplatelet Drug Resistance in Patients With Drug Eluting Coronary Stents
It is recommended that patients who have drug-eluting stents placed in their coronary arteries take aspirin and Plavix (Clopidogrel) for at least a year.
- Trial name
- NCT00589862
- Testing
- Plavix (Clopidogrel)
- Where
- United States
- Sponsor
- Creighton University
Coronary Artery Disease
A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment
research topic:helios After registration of clinical research bidders:kinhely bio-tech Co.Ltd study design:A prospective single treatment group multicenter clinical study Number of patients:Included in the subjects of 800 cases…
- Trial name
- Pro-HOPE (NCT01880879)
- Testing
- helios stent
- Where
- China
- Volunteers
- 800 people
- Sponsor
- Kinhely Bio-tech Co., Ltd.
Coronary Artery Disease
FUNctional eFficacy of Hybrid coronAry REvascularization
The purpose of the study is to compare iFR-guided hybrid coronary revascularization (HCR) and traditional coronary artery bypass grafting (CABG) in terms of a functional efficacy of revascularization assessed by weighted average…
- Trial name
- FUNFARE (NCT04698460)
- Testing
- Hybrid coronary revascularization, Coronary artery bypass grafting
- Where
- Russia
- Volunteers
- 13 people
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Coronary Artery Disease
Post-marketing Registry of Inspiron Sirolimus Eluting Coronary Stent
Post-marketing, prospective, multicentric, non-randomized registry to evaluate the safety and efficacy of Inspiron Sirolimus Eluting Coronary Stent at the treatment of "real-world" patients.
- Trial name
- Inspiron RL II (NCT03263260)
- Testing
- implant
- Where
- Brazil
- Volunteers
- 2,504 people
- Sponsor
- Scitech Produtos Medicos SA